Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Overexpressing Node-Positive Breast Cancer

1/3/02


Click here to start


Table of Contents

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Overexpressing Node-Positive Breast Cancer

N9831: Intergroup Trial for Node ?, HER2 ? Breast Cancer

Her2 Eligibility Criteria for N9831 as Determined by Local Testing

Her2 Central Testing

N9831: HER2 Testing Results

Comparison of Local/Central IHC Review

Comparison of Local/Central FISH Review

HercepTest/FISH Central Review of 119 Specimens

Comparison of Central HercepTest and Vysis FISH

Summary of Central HercepTest and Vysis FISH Results

Proposed Modifications for N9831

Author: Martin Kranzbaum